Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.43 |
| ▸ | REN | P00797 | 2/20 | 0.40 |
| ▸ | GRB2 | P62993 | 1/20 | 0.40 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376028 | 1.00 | OPRM1 (0.43) | OPRM1OPRD1CAPN1RENGRB2 | |
| SCHEMBL31140016 | 0.95 | CAPN1 (0.41) | OPRM1OPRD1CAPN1RENGRB2 | |
| SCHEMBL30013216 | 0.95 | CAPN1 (0.41) | OPRM1OPRD1CAPN1RENGRB2 | |
| SCHEMBL30211634 | 0.95 | CAPN1 (0.43) | OPRM1OPRD1CAPN1RENGRB2 | |
| SCHEMBL29396694 | 0.94 | CAPN1 (0.41) | OPRM1OPRD1CAPN1RENBDKRB2 | |
| SCHEMBL31115696 | 0.94 | CAPN1 (0.41) | OPRM1OPRD1CAPN1RENBDKRB2 | |
| SCHEMBL29757422 | 0.93 | CAPN1 (0.51) | OPRM1OPRD1CAPN1GRB2CTSB | |
| SCHEMBL31259075 | 0.93 | CAPN1 (0.44) | OPRM1OPRD1CAPN1GRB2BDKRB2 | |
| SCHEMBL30220497 | 0.91 | REN (0.46) | OPRM1OPRD1RENGRB2 | |
| SCHEMBL30139043 | 0.90 | REN (0.39) | OPRM1OPRD1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745153-A1 | GLP-1, GIP AND GCG RECEPTOR TRIAGONIST AND USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| WO-2025016303-A1 | GLP-1, GIP AND GCG RECEPTOR TRIAGONIST AND USE THEREOF | 北京拓界生物医药科技有限公司 | 2025-01-23 | — | — | WO | claimed |
| US-20240209054-A1 | GIP AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2024-06-27 | — | — | US | claimed |
| US-11814417-B2 | GIP agonist compounds and methods | ZEALAND PHARMA A/S (DK) | 2023-11-14 | — | — | US | claimed |
| CN-115572326-A | Triplex agonists of GLP-1, GCG and GIP receptors | 广东东阳光药业有限公司 | 2023-01-06 | — | — | CN | claimed |
| WO-2022268029-A1 | TRIPLE AGONIST FOR GLP-1, GCG AND GIP RECEPTORS | 广东东阳光药业有限公司 | 2022-12-29 | — | — | WO | claimed |
| EP-3985016-A1 | GIP AGONIST COMPOUNDS AND METHODS | Zealand Pharma A/S (DK) | 2022-04-20 | — | — | EP | claimed |
| US-20220041676-A1 | GIP AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2022-02-10 | — | — | US | claimed |
| EP-4745153-A1 | GLP-1, GIP AND GCG RECEPTOR TRIAGONIST AND USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| EP-4593864-A1 | METHODS FOR TREATING OBESITY | Zealand Pharma A/S (DK) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025016303-A1 | GLP-1, GIP AND GCG RECEPTOR TRIAGONIST AND USE THEREOF | 北京拓界生物医药科技有限公司 | 2025-01-23 | — | — | WO | disclosed |
| CN-115572326-B | Triple agonists of GLP-1, GCG and GIP receptors | 广东东阳光药业股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-111825758-B | GLP-1 and GIP co-agonist compounds | 上海翰森生物医药科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240209054-A1 | GIP AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2024-06-27 | — | — | US | disclosed |
| CN-110312520-B | Treatment of neurological disorders | 兰卡斯特大学企业有限公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-115572326-A | Triplex agonists of GLP-1, GCG and GIP receptors | 广东东阳光药业有限公司 | 2023-01-06 | — | — | CN | disclosed |
| WO-2022268029-A1 | TRIPLE AGONIST FOR GLP-1, GCG AND GIP RECEPTORS | 广东东阳光药业有限公司 | 2022-12-29 | — | — | WO | disclosed |
| EP-3985016-A1 | GIP AGONIST COMPOUNDS AND METHODS | Zealand Pharma A/S (DK) | 2022-04-20 | — | — | EP | disclosed |
| US-20220041676-A1 | GIP AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2022-02-10 | — | — | US | disclosed |
| US-20220033457-A1 | TREATMENT OF NEUROLOGICAL DISEASES | UNIVERSITY OF LANCASTER (GB) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209054-A1 | GIP AGONIST COMPOUNDS AND METHODS | GIPR, GLP1R, GPR119 | OPRM1 1117/4885OPRD1 1008/4885CAPN1 3702/4885 |
| US-11814417-B2 | GIP agonist compounds and methods | GIPR, GLP1R, GPR119 | OPRM1 1117/4885OPRD1 1008/4885CAPN1 3702/4885 |
| US-20220041676-A1 | GIP AGONIST COMPOUNDS AND METHODS | GIPR, GLP1R, GPR119 | OPRM1 1117/4885OPRD1 1008/4885CAPN1 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.